Sep 10th 2012 - Edison Investment Research today published a report on outlook entitled "Resistance Is Futile". In summary, the report says:
NovaBay is entering a potentially transformational 12-month period – multiple Phase IIb trial read-outs offer major share price catalysts and positive data would provide clear validation of its novel anti-infective technology. Lead compound NVC-422 is being studied in three significant unmet needs and affirmative results could lead to considerable partnering demand. We believe the potential in NovaBay’s Aganocide compounds, with proven ability to overcome and avoid resistance issues that plague the anti-infective market, is not reflected in its current market capitalisation. We value NovaBay at $53m, or $1.86 per share, based on a sum-of-the-parts DCF valuation.
Edison Investment Research is a leading international investment research company. It has won industry recognition, with awards both in the UK and internationally. The team of 95 includes over 60 analysts supported by a department of supervisory analysts, editors and assistants. Edison writes on more than 400 companies across every sector and works directly with corporates, fund managers, investment banks, brokers and other advisers. Edison’s research is read by institutional investors, alternative funds and wealth managers in more than 100 countries. Edison, founded in 2003, has offices in London, New York and Sydney and is authorised and regulated by the Financial Services Authority (www.fsa.gov.uk/register/firmBasicDetails.do?sid=181584). more »